Geron Corporation (GERN) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[4], including 2 Phase 3[1], 1 Phase 2[2], 1 Phase 1[3].
Trial NCT02598661[5] evaluates Imetelstat Sodium in Myelodysplastic Syndromes with a target enrollment of 289 participants. Trial NCT04576156[6] evaluates Imetelstat in Myelofibrosis with a target enrollment of 327 participants.
GERN has 3 Form 4 insider filings recorded at the SEC in the past 30 days[7].